Table 3

Summary of relative abundance of radioactive metabolites accounting for >1% of dose in urine, feces, and bile

Excretion MatrixRecovery DataDrug or Metabolite Name
Percent of dose profiledPercent of dose not extracted3-aSN-38G (M3)NPC (M9)APC (M11)CPT-11SN-38 (M17)
All patients (n = 7)
 Urine30.2  ± 6.61.25  ± 1.553.02  ± 0.770.14  ± 0.082.23  ± 1.5322.40  ± 5.500.43  ± 0.12
 Feces62.0  ± 7.69.86  ± 3.770.27  ± 0.171.36  ± 0.948.29  ± 2.9532.31  ± 4.478.24  ± 2.51
Total92.211.13.291.5010.554.78.67
Patient No. 5—Bile Duct Exteriorized
 Urine45.82.6712.010.097.7321.770.90
 Feces13.72.710.000.321.666.262.78
 Bile29.73.182.670.303.9018.460.44
Total89.38.5614.70.7113.346.54.12

Parent drug and metabolite abundance are expressed as percentage of administered dose and were determined by quantitative radiometric HPLC. Two minor radioactive peaks denoted M5 and M7 accounted for 0.23 and 0.98% of dose, respectively. M5 was the hydroxy acid form of CPT-11 in equilibrium with the lactone form and was observed as a consequence of sample concentration. All other minor radioactive peaks (12 of 19 total peaks) collectively accounted for a mean of less than 1.18% of dose. Differences across gender were not significant. Bile exteriorized patient 5 was excluded from calculation of means.

  • 3-a Based on extraction efficiency and recovery after SPE and concentration steps.